Insights
Search Results
Client Highlights
4.29.26
Firm Advises Match Group on $100 Million Investment in Sniffies
On April 27, 2026, Match Group, a leading provider of digital technologies designed to help people make meaningful connections, announced a $100 million investment in Sniffies, a map-based platform serving non-heterosexual men. The investment represents a significant minority ownership stake and includes the option to acquire the remaining equity in the future. Sniffies will continue to operate independently and remain founder-led, with Match Group supporting the team's vision and growth. Wilson Sonsini Goodrich & Rosati advised Match Group on the transaction.
Client Highlights
2.13.26
Firm Advises Microchip Technology on Offering of $900 Million of Convertible Senior Notes
On February 11, 2026, Microchip Technology completed an offering of $900 million aggregate principal amount of convertible senior notes due 2030 in a private transaction. The offering amount included the exercise in full of the option that Microchip had granted to the initial purchasers to purchase up to an additional $100 million of notes. In connection with the offering, Microchip entered into privately negotiated capped call transactions with certain of the initial purchasers or their respective affiliates and other financial institutions.
Client Highlights
2.05.26
Wilson Sonsini Advises Fair Square Medicare on Acquisition by Senior Market Sales
On January 30, 2026, Senior Market Sales®(SMS), one of the industry’s premier insurance marketing organizations (IMOs), announced that it has acquired Fair Square Medicare, a technology-driven health care platform designed to simplify the Medicare experience for seniors. This strategic acquisition enhances SMS’ suite of digital tools and reinforces its commitment to providing guidance to seniors as they navigate Medicare coverage. Wilson Sonsini Goodrich & Rosati advised Fair Square on the transaction.
Client Highlights
2.05.26
Wilson Sonsini Advises SpyGlass Pharma on $150 Million IPO
On February 5, 2026, SpyGlass Pharma, Inc., a late-stage biopharmaceutical company, announced the pricing of its initial public offering of 9,375,000 shares of its common stock at a public offering price of $16.00 per share. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by SpyGlass Pharma, are expected to be approximately $150 million. Wilson Sonsini Goodrich & Rosati advised SpyGlass Pharma on the transaction.
SpyGlass Pharma has granted the underwriters a 30-day option to purchase up to an additional 1,406,250 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All shares of common stock are being offered by SpyGlass Pharma. SpyGlass Pharma’s common stock is expected to begin trading on the Nasdaq Global Select Market on February 6, 2026, under the ticker symbol “SGP.” The offering is expected to close on February 9, 2026, subject to the satisfaction of customary closing conditions.
The Wilson Sonsini team that advised SpyGlass Pharma includes:
SpyGlass Pharma has granted the underwriters a 30-day option to purchase up to an additional 1,406,250 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All shares of common stock are being offered by SpyGlass Pharma. SpyGlass Pharma’s common stock is expected to begin trading on the Nasdaq Global Select Market on February 6, 2026, under the ticker symbol “SGP.” The offering is expected to close on February 9, 2026, subject to the satisfaction of customary closing conditions.
The Wilson Sonsini team that advised SpyGlass Pharma includes:
Client Highlights
2.05.26
Wilson Sonsini Advises Zscaler on Acquisition of SquareX
On February 05, 2026, Zscaler, a leader in cloud security, announced it has acquired SquareX, to further extend Zero Trust capabilities into the browser for the AI era. This acquisition will help redefine browser security, allowing organizations to embed lightweight extensions into any browser, providing increased security, and eliminating the need for third-party browsers. The acquisition closed on February 5, 2026. Terms of the transaction have not been disclosed. Wilson Sonsini Goodrich & Rosati advised Zscaler on the transaction.
Client Highlights
1.08.26
Wilson Sonsini Advises Ventyx Biosciences on $1.2 Billion Acquisition by Eli Lilly
On January 7, 2026, Eli Lilly and Company announced that it has entered into a definitive agreement to acquire Ventyx Biosciences, Inc., a San Diego-based clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammatory-mediated diseases. Under the terms of the agreement, Lilly will acquire all the outstanding shares of Ventyx in an all-cash transaction, valuing at approximately $1.2 billion. Wilson Sonsini is advising Ventyx on the transaction.
Client Highlights
12.19.25
Wilson Sonsini Advises Cursor on Acquisition of Graphite
On December 19, 2025, Cursor, the leading AI development platform, announced that it has signed a definitive agreement to acquire Graphite, a start-up that uses AI to review code. The financial terms of the deal were not disclosed. Wilson Sonsini Goodrich & Rosati advised Cursor on the transaction.
The transaction brings together best-in-class tools for creating, reviewing, and merging code in the AI age. Graphite will continue to operate independently, with the same team and product. According to Cursor, in the coming months the two companies will explore connecting their products, for instance with tighter integrations between local development and pull requests and smarter code review that learns from both systems.
The Wilson Sonsini team that advised Cursor on the transaction included:
M&A
Rich Mullen
Ryan Cooper
Hallee Moore
Valerie Lopez
Drew Downing
The transaction brings together best-in-class tools for creating, reviewing, and merging code in the AI age. Graphite will continue to operate independently, with the same team and product. According to Cursor, in the coming months the two companies will explore connecting their products, for instance with tighter integrations between local development and pull requests and smarter code review that learns from both systems.
The Wilson Sonsini team that advised Cursor on the transaction included:
M&A
Rich Mullen
Ryan Cooper
Hallee Moore
Valerie Lopez
Drew Downing
Client Highlights
12.17.25
Wilson Sonsini Advises Hexagon Bio on Multimillion-Dollar Joint Venture with Corteva
On December 16, 2025, Corteva, a global leader in agricultural technology, and Hexagon Bio, a biotechnology company pioneering a new way to discover nature-derived medicine, announced a multimillion-dollar joint venture (JV) to accelerate the development of new crop protection solutions inspired by nature. The JV is the first in the agriculture sector for Hexagon Bio and the first in the pharmaceutical industry for Corteva. Wilson Sonsini Goodrich & Rosati advised Hexagon Bio on the transaction.
The partnership brings together Corteva’s billion-dollar nature-inspired crop protection franchises and bacterial natural product discovery capabilities with Hexagon Bio’s natural-product discovery platform to advance the companies’ respective pipelines across agriculture and human health. Hexagon Bio’s platform combines microbial genetics, artificial intelligence, chemistry, and synthetic biology to identify and characterize novel natural products, uncovering diverse mechanisms not obvious from the chemical structure or conventional techniques and allowing for more efficient molecule discovery.
The Wilson Sonsini team that advised Hexagon Bio on the transaction included Ken Clark, Norm Hovijitra, Aleks Vitomirov, Lance Brady, Christina Poulsen, Adrian Broderick, Sara Pollock, Jacob Morales, Henry Yen, Myra Sutanto Shen, and Rob Sherrill.
For more information, please see the companies’ joint news release.
The partnership brings together Corteva’s billion-dollar nature-inspired crop protection franchises and bacterial natural product discovery capabilities with Hexagon Bio’s natural-product discovery platform to advance the companies’ respective pipelines across agriculture and human health. Hexagon Bio’s platform combines microbial genetics, artificial intelligence, chemistry, and synthetic biology to identify and characterize novel natural products, uncovering diverse mechanisms not obvious from the chemical structure or conventional techniques and allowing for more efficient molecule discovery.
The Wilson Sonsini team that advised Hexagon Bio on the transaction included Ken Clark, Norm Hovijitra, Aleks Vitomirov, Lance Brady, Christina Poulsen, Adrian Broderick, Sara Pollock, Jacob Morales, Henry Yen, Myra Sutanto Shen, and Rob Sherrill.
For more information, please see the companies’ joint news release.
Client Highlights
10.13.25
Wilson Sonsini Advises Fivetran on Merger with dbt Labs
On October 13, 2025, Fivetran, a global leader in automated data movement, announced that it signed a definitive agreement to merge with dbt Labs, a pioneer of modern data transformation, in an all-stock deal. The combined company will be approaching $600 million in annual recurring revenue. The transaction marks significant consolidation in the data tooling market as enterprises race to adapt infrastructure for artificial intelligence applications. Wilson Sonsini Goodrich & Rosati advised Fivetran on the transaction.
Client Highlights
9.22.25
Wilson Sonsini Advises Netskope on IPO
On September 17, 2025, Netskope, a leader in modern security and networking for the cloud and AI era, announced the pricing of its initial public offering of 47,800,000 shares of its Class A common stock at a public offering price of $19.00 per share. The shares began trading on the Nasdaq Global Select Market on September 18, 2025, under the ticker symbol “NTSK.” The offering closed on September 19, 2025. Additionally, on September 22, 2025, Netskope announced the full exercise of its over-allotment option of 7,170,000 shares of Class A common stock. Wilson Sonsini Goodrich & Rosati advised Netskope on the transaction.
Client Highlights
9.19.25
Wilson Sonsini Advises Anysphere on Acquisition of Koala
Anysphere, the company behind the artificial intelligence coding application Cursor, acquired Koala, an AI-powered customer relationship management start-up. The acquisition brings Koala’s top engineers to Cursor to help build out a dedicated enterprise-readiness team. Wilson Sonsini Goodrich & Rosati advised Anysphere on the transaction.
Client Highlights
9.17.25
Firm Advises Planet Labs on $460 Million Convertible Senior Notes Offering
On September 12, 2025, Planet Labs, PBC, completed an upsized offering of $460 million aggregate principal amount of convertible senior notes due 2030, in a private transaction. The offering amount included the exercise in full of the option that Planet Labs had granted to the initial purchasers to purchase up to an additional $60 million of notes. In connection with the offering, Planet Labs entered into privately negotiated capped call transactions with an affiliate of one of the initial purchasers and certain other financial institutions. Wilson Sonsini Goodrich & Rosati advised Planet Labs on the transaction.